Safety and Efficacy of Furoquintinib Combining with PD-L1 Inhibitor in the Treatment for Advanced MSS mCRC
Metastatic colorectal cancer(mCRC)remains a significant global health challenge,necessitating innovative approaches to enhance treatment outcomes.To explore the feasibility of furquintinib combined with an anti-PD-L1 inhibitor in treating mCRC,a retrospective analysis was conducted to compare the efficacy and safety of microsatellite stability(MSS)or proficient mismatch repair(pMMR)mCRC patients who received furquintinib and a PD-L1 inhibitor(the target and immunotherapy group)with those who received only furquintinib(the target group).Data from patients with advanced MSS/pMMR mCRC at the Affiliated Lihuili Hospi-tal,Ningbo University,spanning from January 2019 to June 2022 were gathered.A comprehensive analysis to assess and compare the efficacy and safety of both groups were conducted.Key parameters examined included the objective response rate(ORR),progres-sion-free survival(PFS),and adverse events(AEs).Statistical analysis was performed using SPSS 25.0 software and GraphPad Prism 8.0.The result showed a total of 40 eligible patients were included in this study,with 19 cases in the target and immunotherapy group and 21 cases in the target group.In the target and immunotherapy group,the total remission rate was 5.0％,while the target group showed no instances of remission.Disease control rates for the two groups were 68.4％for the target and immunotherapy group and 52.3％for the target group.Notably,the median PFS for the target and immunotherapy group(5.8 months)exceeded that of the target group(4.5 months),with statistical significance(P=0.0135).AEs were comparable between the two groups,and only three patients(7.5％)experienced treatment-related third-grade AEs;importantly,there were no treatment-related fatalities.This study provides compelling evidence supporting the combination therapy of furquintinib and a PD-L1 inhibitor for mCRC patients.The data demonstrated that the combination therapy not only yielded improved survival benefits but also maintained manageable levels of toxic reactions when compared to furquintinib monotherapy.
NETL
NSTL
万方数据
